Related Experiment Video
Updated: Jun 22, 2025
Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation
Published on: October 1, 2012
Risk of Hematologic Malignancies in Patients with Inflammatory Bowel Disease: A Meta-Analysis of Cohort Studies
Xiaoshuai Zhou1, Qiufeng Zhang2, Dongying Wang2
1Department of Anus and Intestine Surgery, Ningbo Yinzhou No. 2 Hospital, Ningbo, China.
Insights
Patients with inflammatory bowel disease (IBD) have a significantly higher risk of developing hematologic malignancies, including specific lymphomas and leukemia, compared to those without IBD.
Area of Science:
- Gastroenterology
- Oncology
- Epidemiology
Background:
- Inflammatory bowel disease (IBD) encompasses chronic conditions like ulcerative colitis and Crohn's disease.
- Emerging evidence suggests a potential link between IBD and the development of hematologic malignancies.
Purpose of the Study:
- To investigate the relationship between IBD and the incidence of hematologic malignancies.
- To quantify the risk of hematologic malignancies in IBD patients compared to non-IBD populations.
Main Methods:
- A comprehensive meta-analysis was conducted.
- Data were extracted from twenty cohort studies published between January 2000 and June 2023.
- Searches were performed across PubMed, Web of Science, Embase, and Cochrane Library databases.
Main Results:
- The overall incidence of hematologic malignancies was 3.05 times higher in IBD patients (p<0.001).
- Both ulcerative colitis (SIR=2.29, p=0.05) and Crohn's disease (SIR=3.56, p=0.005) showed increased malignancy risk.
- Specific risks were elevated for non-Hodgkin's lymphoma (SIR=1.70, p=0.01), Hodgkin's lymphoma (SIR=3.47, p=0.002), and leukemia (SIR=3.69, p<0.001).
Conclusions:
- Patients with IBD face a significantly elevated risk of developing hematologic malignancies.
- This increased risk applies to specific conditions including non-Hodgkin's lymphoma, Hodgkin's lymphoma, and leukemia.
- The findings highlight the importance of monitoring IBD patients for hematologic malignancy development.
Background/Aims:
Inflammatory bowel disease (IBD) may contribute to the development of hematologic malignancies. In this study, the potential relationship between IBD and hematologic malignancies was investigated.
Methods:
We searched the PubMed, Web of Science, Embase, and Cochrane Library databases for all cohort studies comparing the incidence of hematologic malignancies in non-IBD populations with that in IBD patients, and we extracted relevant data from January 2000 to June 2023 for meta-analysis.
Results:
Twenty cohort studies involving 756,377 participants were included in this study. The results showed that compared with the non-IBD cohort, the incidence of hematologic malignancies in the IBD cohort was higher (standardized incidence ratio [SIR]=3.05, p<0.001). According to the specific types of IBD, compared with the non-IBD patients, the incidences of hematologic malignancies in ulcerative colitis patients (SIR=2.29, p=0.05) and Crohn's disease patients (SIR=3.56, p=0.005) were all higher. In the subgroup analysis of hematologic malignancy types, compared with the control group, the incidences of non-Hodgkin's lymphoma (SIR=1.70, p=0.01), Hodgkin's lymphoma (SIR=3.47, p=0.002), and leukemia (SIR=3.69, p<0.001) were all higher in the IBD cohort.
Conclusions:
The incidence of hematologic malignancies, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, and leukemia is higher in patients with IBD (ulcerative colitis or Crohn's disease) than in non-IBD patients.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...